多发性胃癌的临床病理特征及辅助化疗对其长期生存的影响:一项倾向评分匹配分析

背景与目的人们对多发性胃癌(multiple gastric cancers,MGC)的临床病理学特征、术后治疗和预后之间的关系知之甚少。在本研究中,我们旨在研究MGC的临床病理学特征以及术后辅助化疗对其长期生存的影响。方法分析2007年1月至2016年12月期间,经根治性胃切除术治疗的胃腺癌患者的临床和病理资料。采用倾向评分匹配法比较MGC和单发性胃癌(solitary gastric cancers,SGC)患者的预后差异及术后辅助化疗对预后的影响。结果在4107例患者中,MGC的发生率为3.2%(133/4107)。匹配前,MGC和SGC患者在胃切除术类型、病理肿瘤分期(pathological tumor stage,pT)、病理淋巴结分期(pathological node stage,pN)和病理肿瘤–淋巴结–转移分期(pathological tumor-node-metastasis stage,pT NM)方面存在差异。按照1∶4比例匹配后,133例MGC患者和532例SGC患者的临床数据具有可比性。整个匹配队列中的5年总生存(overall survival,OS)率为56.6%,MGC组和SGC组分别为48.1%和58.7%(P=0.013)。多变量分析结果显示,MGC、年龄、pT分期、pN分期和辅助化疗是OS的独立预测因素(均P<0.05)。分层分析结果表明,在未接受辅助化疗的进展期胃癌(advanced gastric cancer,AGC)患者中,进展期MGC患者的5年OS率低于SGC患者(分别为34.0%和46.1%;P=0.025)。而进行辅助化疗的进展期MGC患者和SGC患者的5年OS率无显著差异(分别为48.0%和53.3%;P=0.292)。此外,我们发现进行辅助化疗的进展期MGC患者的5年OS率显著高于未接受辅助化疗的患者(分别为48.0%和34.0%,P=0.026)。结论进展期MGC患者的生存率低于SGC患者,术后辅助化疗可能会显著改善MGC患者的长期预后。

Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers:a propensity score matching analysis

Background:Little is known about the correlation between the clinicopathological features,postoperative treatment,and prognosis of multiple gastric cancers(MGCs).In this study,we aimed to investigate the correlation between these features and the impact of postoperative adjuvant chemotherapy on the long-term survival of patients with MGC.Methods:The clinical and pathological data of patients diagnosed with gastric adenocarcinoma who had radical gastrectomy from January 2007 to December 2016 were analyzed.Using propensity score matching,the prognostic differences,and the impact of postoperative adjuvant chemotherapy between those with MGC and solitary gastric cancers(SGC)were compared.Results:Among the 4107 patients investigated,the incidence of MGC was 3.2%(133/4107).Before matching,patients with MGC and SGC had disparities in the type of gastrectomy,pathological tumor stage(pT),pathological node stage(pN),and pathological tumor-node-metastasis stage(pTNM).After a 1:4 ratio matching,the clinical data of 133 cases of MGC and 532 cases of SGC were found to be comparable.The 5-year overall survival(OS)rate was 56.6%in the entire matched cohort,48.1%in the MGC group,and 58.7%in the SGC group(P=0.013).Multivariate analysis revealed that MGC,age,pT stage,pN stage,and adjuvant chemotherapy were independent predictors of OS(all P<0.05).Stratified analyses demonstrated that for the cohort of advanced gastric cancer(AGC)patients who did not had adjuvant chemotherapy,the 5-year OS rate of advanced cases of MGC was inferior than that of SGC patients(34.0%vs.46.1%,respectively;P=0.025)but there were no significant difference in the 5-year OS rate between advanced MGC and SGC patients who had adjuvant chemotherapy(48.0%vs.53.3%,respectively;P=0.292).Further,we found that the 5-year OS rate of advanced MGC who had adjuvant chemotherapy was significantly higher than those who did not had adjuvant chemotherapy(48.0%vs.34.0%,P=0.026).Conclusions:Patients with advanced MGC was identified as having a poorer survival as to SGC patients,but the implementation of postoperative adjuvant chemotherapy showed that it had the potential to significantly improve the long-term prognoses of MGC patients.